Qiubin LIN
Dr. Qiubin Lin is the founder and CEO of Delonix Bioworks, with 15+ years of experience in synthetic biology research and biotech entrepreneurship. He founded Delonix in 2021, focusing on next-generation bacterial vaccine development. Delonix notably became the first biotech in China to obtain IND approval for its proprietary engineered OMV vaccine platform. The company secured a $14 million seed round led by BIVF and IDG Capital, following its recognition as the winner of the first Boehringer Ingelheim Innovation Prize in China. Dr. Lin previously served as Senior Research Officer at HKU-ZIRI and co-founded PreciVax Therapeutics. He received his Ph.D. in Biomedical Sciences from HKU and has been recognized with multiple innovation and talent awards in China.
Abstracts this author is presenting: